Teva Pharmaceutical Industries Ltd (TEVA) Stock Price & Analysis

Teva Pharmaceutical Industries Ltd (TEVA) fell 0.71% to USD 36.36 as of September 8, 2026 at 03:33 UTC, according to Nexqual real-time market data.

TEVA last closed at USD 36.36; the session ranged USD 36.13–36.93 on volume of 7,386,212 shares. Market capitalization is —, with a 52-week range of USD 18.21–38.37 (NYQ). Source: Nexqual, September 8, 2026 at 03:33 UTC.

Key Statistics (as of September 8, 2026 at 03:33 UTC)

Technical Analysis (TEVA)

Nexqual's technical model rates TEVA "NEUTRAL" based on 3 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 03:33 UTC.

From Teva Pharmaceutical Industries Ltd's Latest SEC 10-K Filing (filed 2026-02-03)

Key Strengths & Strategy (as disclosed to the SEC)

• Furthermore, our trade secrets and proprietary technology may otherwise become known or be independently developed by our competitors or we may not be able to maintain the confidentiality of information relating to such products.
• If we are unable to adequately protect our technology, trade secrets or proprietary know-how, or enforce our intellectual property rights, our results of operations, financial condition and cash flows could suffer.
• Any manipulation, theft, loss and/or fraudulent use of customer, employee or proprietary data as a result of a cyber-attack targeting us or one of our third-party service providers could subject us to significant litigation, liability and costs, as well as adversely impact our reputation with customers and regulators.
• We may not be successful in seeking or consummating appropriate opportunities to enable us to execute on our business strategy.

Partnerships

• In 2016, we paid a monetary fine for FCPA violations and entered into a three-year deferred prosecution agreement with the DOJ, which included retaining an independent compliance monitor.
• In addition, we, or the partners with which we may enter into licensing or other collaboration agreements, may not be able to perform effectively under such agreements, impairing our ability to monetize opportunities related to them.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 03:33 UTC. This page is informational and not investment advice.